Management of Postural (Orthostatic) Hypotension
Begin with non-pharmacological interventions as first-line therapy, and add midodrine (5-20 mg three times daily) or fludrocortisone (0.1-0.3 mg once daily) as adjunctive pharmacological therapy when non-pharmacological measures alone are insufficient. 1
Non-Pharmacological Management (First-Line)
Immediate Lifestyle Modifications
- Increase fluid intake to 2-3 liters per day and salt intake to 10 grams of NaCl daily (unless hypertension is present) 1
- Rapid cool water ingestion is effective for combating orthostatic intolerance and post-prandial hypotension 1
- Sleep with head of bed elevated 10 degrees to prevent nocturnal polyuria, maintain favorable body fluid distribution, and ameliorate nocturnal hypertension 1
Mechanical Interventions
- Abdominal binders and compression stockings reduce gravitational venous pooling, particularly effective in older patients 1
- Physical counterpressure maneuvers (leg crossing, squatting) should be encouraged in patients with warning symptoms who are able to perform them 1
Additional Measures
- Discontinue or rationalize offending medications that may exacerbate hypotension 2, 3
- Avoid large carbohydrate-rich meals to prevent post-prandial hypotension 4
- Limit alcohol consumption 4
- Use walking sticks for support 1
- Frequent small meals rather than large ones 1
- Judicious exercise of leg and abdominal muscles, especially swimming 1
Pharmacological Management (Adjunctive Therapy)
First-Line Pharmacological Agents
Midodrine is the most evidence-based pharmacological option with three randomized placebo-controlled trials demonstrating efficacy 1:
- Dosing: 5-20 mg three times daily
- Mechanism: Alpha-agonist that increases blood pressure in both supine and upright postures
- Evidence: Proven to ameliorate symptoms of orthostatic hypotension
- Caveat: Not a cure and not helpful in all patients, but very useful in some 1
Fludrocortisone is supported by observational studies and one double-blind trial 1:
- Dosing: 0.1-0.3 mg once daily
- Mechanism: Mineralocorticoid that stimulates renal sodium retention and expands fluid volume
- Evidence: Treated patients showed less symptoms with higher blood pressures 1
Second-Line and Specialized Agents
Droxidopa has consistent evidence for improving orthostatic symptoms and is FDA-approved 5:
- Recommended as first-line therapy alongside midodrine
- Particularly useful in neurogenic orthostatic hypotension
Pyridostigmine can be used in patients who fail to respond to midodrine or fludrocortisone 4:
- Shows additional benefits in combination therapies 5
Atomoxetine shows promise with emerging evidence 4:
- Low-dose atomoxetine is particularly effective in central autonomic failure
- May prove to be a viable alternative treatment option
- Moderate efficacy demonstrated in recent studies 5
Specialized Situations
Desmopressin: For patients with nocturnal polyuria 1
Octreotide: For post-prandial hypotension 1, though evidence remains limited and it's reserved for refractory cases 5
Erythropoietin: In patients with anemia contributing to orthostatic hypotension 1
Critical Clinical Considerations
The Supine Hypertension Challenge
A major pitfall in treating orthostatic hypotension is worsening coexisting supine hypertension 6, 7. This requires:
- Careful monitoring of both upright and supine blood pressures
- Consideration of timing medications to avoid nighttime supine hypertension
- Potentially switching antihypertensive medications to bedtime administration 4
- Head-up tilt sleeping becomes even more critical in these patients 1
Treatment Algorithm
- Start with comprehensive medication review - identify and discontinue causative agents
- Implement all applicable non-pharmacological measures simultaneously - these form the foundation
- Add midodrine if symptoms persist despite adequate non-pharmacological therapy
- Consider fludrocortisone as alternative or addition if midodrine is insufficient or not tolerated
- Progress to second-line agents (pyridostigmine, atomoxetine, droxidopa) for refractory cases
- Reserve specialized agents (octreotide, desmopressin) for specific clinical scenarios
Important Caveats
- Treatment efficacy is often modest with short duration of action 6
- Approximately 20% of patients experience syncope recurrence despite adequate treatment, often due to associated vasodepressor reflex mechanisms 1
- Mechanism-based treatment selection informed by physiological phenotyping is increasingly important to explain therapeutic heterogeneity and match patients to interventions 6
- The future of management depends on treating orthostatic hypotension and supine hypertension as a coupled disorder of impaired blood pressure control 6
Special Population: Adolescents
For adolescents (12-19 years old), prioritize non-pharmacological interventions first 8. If pharmacological treatment becomes necessary, midodrine has been studied in two small randomized controlled trials in pediatric populations with significant benefit 8.